GPCR

Structure Therapeutics Inc. American Depositary Shares (GPCR) | Rumor.io

Structure Therapeutics

GPCR

Attention (50-day avg)0%

Attention rank (50-day avg)#1,026

Bullish sentiment (50-day avg)82%

Price to earnings ratio-17.6

Market capitalization2.5B

Earnings per share-3.03

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-141.2M

Social

What share of all stock conversation is about GPCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 8

Structure Therapeutics Inc. reported positive clinical trial results for its weight management drugs ACCG-2671 and aleniglipron, showing significant body weight reductions and favorable safety profiles.
The trial data showed that ACCG-2671 achieved a 3% weight loss after a single dose, while aleniglipron achieved up to 16% weight loss at 72 weeks, but investors were disappointed by the results.
The company's stock price fell after the trial data was released, with some analysts suggesting that the data was not strong enough to justify the company's valuation, and that the bar for oral GLP-1 drugs is already high.

Generated by AI

Sentiment

Of the messages about GPCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	40%	53.57% -32.69	81.77% +25.52	67.45% -11.82
Bearish	60%	46.43% +32.69	18.23% -25.52	32.55% +11.82

Bullish· Jan 20

$GPCR shares have hit all-time highs, and buying the dips after data releases can be a solid investment strategy, as seen with the stock's 40% increase in the last month.
Structure Therapeutics, the company behind $GPCR, has been upgraded to Buy at Goldman Sachs with a price target of $102, indicating a strong market opinion on the asset's potential.
$GPCR has a high potential for a buyout, with some analysts speculating that a big company like Pfizer or Merck could acquire it for $20-30 billion, which would translate to a buyout price of around $300 per share.

Bearish· Dec 8

The company's decision not to release specific safety data for its aleniglipron treatment may raise concerns with the FDA and lead to a stock dump.
The company's CEO, Dr. Raymond C. Stevens, has been accused of stock manipulation and hiding safety data, which could have serious consequences.
The company's Phase 2 trial results were disappointing, with many investors expressing frustration and disappointment with the data.

Generated by AI

Topics

Of the messages about GPCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	83.33%	80.06%	80.16%
Technical Analysis	100%	16.67%	0.31%	5.76%
Analysts	0%	0%	19.63%	10.12%
Controversies	0%	0%	0%	3.17%
Earnings	0%	0%	0%	0.09%
Macro	0%	0%	0%	0.7%

Mar 16

Structure Therapeutics' aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks in the Phase 2 ACCESS II study.
The company plans to initiate a pivotal Phase 3 study for aleniglipron in obesity in the second half of 2026, with top-line results expected in the same period for multiple clinical studies, including the ACCESS-1 OLE study and a body composition study.
Aleniglipron demonstrated a tolerability profile consistent with the GLP-1 receptor agonist class and a compelling safety profile with no off-target events, with an overall AE-related discontinuation rate of 2% in the OLE and 3.4% in the body composition study.

Generated by AI

Community

Of the messages about GPCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	72.55%	81.43%	57.21%
Newcomers	0%	27.45%	18.57%	42.79%

Regulars· Sep 8

The company reported positive clinical data for its oral small molecule amylin and GLP-1 programs, but some regulars are concerned about liver enzyme elevation and other potential side effects.
The Phase 3 trial results showed a plateau in efficacy for the Aleniglipron program, and some participants are questioning the company's decision to release the data, citing a high bar for oral GLP-1 drugs.
The company's cash reserves are substantial, with $1.5 billion in the bank, but some regulars are concerned about the potential for gastrointestinal side effects at active amylin doses.

Newcomers· May 17

The newcomer is highlighting the surge in GPCR stock, linking it to broader trends in obesity treatment innovations.
The user is cautioning that sustainability of such stocks is a concern, questioning whether market demand is genuine or driven by speculation.
The post suggests that recent news may be a factor in the surge in interest in GPCR.

Generated by AI

Structure Therapeutics (GPCR) has put fresh clinical data for its oral obesity pipeline in front of investors, highlighting results from early stage ACCG-2671 studies and longer term aleniglipron weight loss trials. Recent trading tells a mixed story for Structure Therapeutics. The 1-day share price return of 5.17% to US$36.81 came after a year-to-date share price decline of 45.96%. Meanwhile, the 1-year total shareholder return of 50.55% points to strong longer term momentum that has cooled...

7d agoYahoo Finance

Structure Therapeutics at Morgan Stanley conference: oral pipeline gains ground

13d agoInvesting.com

Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?

Structure Therapeutics Inc. (NASDAQ:GPCR) reported September 8 results for ACCG-2671, an oral dual amylin and calcitonin receptor agonist. The single-dose portion of a Phase 1/2a trial enrolled 31 healthy adults without obesity. Six participants receiving 10 milligrams recorded a mean 3.3% body-weight reduction at day 24. For investors, the attraction is measurable activity after one […]

19d agofinance.yahoo.com

Structure Therapeutics at Cantor conference: oral obesity push advances

19d agoInvesting.com

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

Tipranks Press Release.

19d agoThe Globe and Mail

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - Slideshow (NASDAQ:GPCR) 2026-09-09

20d agoSeeking Alpha

Also Discussed

Investors talking about GPCR also mention

#	Name	Attention
1	MTSR - Metsera, Inc.	——
2	TERN - Terns Pharmaceuticals, Inc.	——
3	Viking Therapeutics, Inc.VKTX	0.18%0
4	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
5	Abivax SAABVX	0.01%-0.01
6	Mineralys Therapeutics, Inc.MLYS	0%+0
7	Wave Life Sciences Ltd.WVE	0%+0
8	ETNB - 89bio, Inc.	——
9	Janux Therapeutics, Inc.JANX	0%0
10	Revolution Medicines, Inc.RVMD	0.01%-0.01

Structure Therapeutics Inc. American Depositary Shares

Healthcare
Biotechnology

Structure Therapeutics Inc. American Depositary Shares represent ownership interests in Structure Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for chronic metabolic and cardiopulmonary diseases with significant unmet medical needs. The company’s current programs center on medicines designed to target G protein-coupled receptors, a broad and important class of biological pathways involved in disease signaling. Its research pipeline includes candidates aimed at obesity and related metabolic conditions, as well as additional therapeutic areas within chronic disease management. Structure Therapeutics operates as a science-driven drug developer, combining discovery, preclinical work, and clinical-stage development to advance treatments intended for long-term use in specialized medical markets. The American Depositary Shares provide a U.S.-traded equity form for the company’s ordinary shares, giving market participants access to a biopharmaceutical business built around oral therapeutics and targeted receptor biology.

Website

Location

601 Gateway Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about GPCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% +0

Sep 8

Structure Therapeutics Inc. reported positive clinical trial results for its weight management drugs ACCG-2671 and aleniglipron, showing significant body weight reductions and favorable safety profiles.
The trial data showed that ACCG-2671 achieved a 3% weight loss after a single dose, while aleniglipron achieved up to 16% weight loss at 72 weeks, but investors were disappointed by the results.
The company's stock price fell after the trial data was released, with some analysts suggesting that the data was not strong enough to justify the company's valuation, and that the bar for oral GLP-1 drugs is already high.

Generated by AI

Sentiment

Of the messages about GPCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	40%	53.57% -32.69	81.77% +25.52	67.45% -11.82
Bearish	60%	46.43% +32.69	18.23% -25.52	32.55% +11.82

Bullish· Jan 20

$GPCR shares have hit all-time highs, and buying the dips after data releases can be a solid investment strategy, as seen with the stock's 40% increase in the last month.
Structure Therapeutics, the company behind $GPCR, has been upgraded to Buy at Goldman Sachs with a price target of $102, indicating a strong market opinion on the asset's potential.
$GPCR has a high potential for a buyout, with some analysts speculating that a big company like Pfizer or Merck could acquire it for $20-30 billion, which would translate to a buyout price of around $300 per share.

Bearish· Dec 8

The company's decision not to release specific safety data for its aleniglipron treatment may raise concerns with the FDA and lead to a stock dump.
The company's CEO, Dr. Raymond C. Stevens, has been accused of stock manipulation and hiding safety data, which could have serious consequences.
The company's Phase 2 trial results were disappointing, with many investors expressing frustration and disappointment with the data.

Generated by AI

Topics

Of the messages about GPCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	83.33%	80.06%	80.16%
Technical Analysis	100%	16.67%	0.31%	5.76%
Analysts	0%	0%	19.63%	10.12%
Controversies	0%	0%	0%	3.17%
Earnings	0%	0%	0%	0.09%
Macro	0%	0%	0%	0.7%

Mar 16

Structure Therapeutics' aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks in the Phase 2 ACCESS II study.
The company plans to initiate a pivotal Phase 3 study for aleniglipron in obesity in the second half of 2026, with top-line results expected in the same period for multiple clinical studies, including the ACCESS-1 OLE study and a body composition study.
Aleniglipron demonstrated a tolerability profile consistent with the GLP-1 receptor agonist class and a compelling safety profile with no off-target events, with an overall AE-related discontinuation rate of 2% in the OLE and 3.4% in the body composition study.

Generated by AI

Community

Of the messages about GPCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	72.55%	81.43%	57.21%
Newcomers	0%	27.45%	18.57%	42.79%

Regulars· Sep 8

The company reported positive clinical data for its oral small molecule amylin and GLP-1 programs, but some regulars are concerned about liver enzyme elevation and other potential side effects.
The Phase 3 trial results showed a plateau in efficacy for the Aleniglipron program, and some participants are questioning the company's decision to release the data, citing a high bar for oral GLP-1 drugs.
The company's cash reserves are substantial, with $1.5 billion in the bank, but some regulars are concerned about the potential for gastrointestinal side effects at active amylin doses.

Newcomers· May 17

The newcomer is highlighting the surge in GPCR stock, linking it to broader trends in obesity treatment innovations.
The user is cautioning that sustainability of such stocks is a concern, questioning whether market demand is genuine or driven by speculation.
The post suggests that recent news may be a factor in the surge in interest in GPCR.

Generated by AI

Structure Therapeutics

Social

Sep 8

Sentiment

Bullish· Jan 20

Bearish· Dec 8

Topics

Mar 16

Community

Regulars· Sep 8

Newcomers· May 17

News

Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus

Structure Therapeutics at Morgan Stanley conference: oral pipeline gains ground

Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?

Structure Therapeutics at Cantor conference: oral obesity push advances

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - Slideshow (NASDAQ:GPCR) 2026-09-09

Also Discussed

Structure Therapeutics Inc. American Depositary Shares

Company Information

Location

News

Structure Therapeutics (GPCR) Gains Fresh Obesity Trial Backing Following Data That Keeps Valuation In Focus

Structure Therapeutics at Morgan Stanley conference: oral pipeline gains ground

Structure Therapeutics (GPCR): Will Repeat Dosing Confirm Its 3.3% Weight-Loss Signal?

Structure Therapeutics at Cantor conference: oral obesity push advances

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management - Slideshow (NASDAQ:GPCR) 2026-09-09

Also Discussed

Social

Sep 8

Sentiment

Bullish· Jan 20

Bearish· Dec 8

Topics

Mar 16

Community

Regulars· Sep 8

Newcomers· May 17